As 2016 draws to a close, we are proud to look back on an outstanding year of new programs and research success for TargetCancer Foundation.
In 2016 TargetCancer Foundation launched several new programs:
– The Evan Schumacher Fund for Rare Cancer Research at TargetCancer Foundation, honoring the memory of Evan Schumacher and raising $75,000 of its initial $100,000 goal to fund new cholangiocarcinoma research fellowships.
– The TargetCancer Foundation Patient Assistance Fund, providing direct financial help to patients for expenses incurred while participating in rare cancer clinical trials.
– The TargetCancer Foundation Advocacy Council, giving volunteers opportunities to become formally involved in TargetCancer Foundation’s work to raise awareness for rare cancers.
In 2016 TargetCancer Foundation also saw continued success in its research programs:
– Our sixth year of funding for innovative cholangiocarcinoma research, totaling close to $600,000.
– Continued funding for groundbreaking research in esophageal cancer, which led to a new immunotherapy clinical trial.
Other highlights:
– Held a successful year of fundraisers with events around the country, ending with our annual gala at Fenway Park which raised over $225,000.
– Hosted a White House Cancer Moonshot Summit, which united an elite group of cancer researchers and advocates around the topic of rare cancers.
– Participated in our second Boston Marathon in 2016, and fielded a new team for 2017.
We’re poised for continued growth and expansion in 2017, and are grateful for the support of so many who are committed to our mission. Onward to 2017!